Moderna Inc. posted better-than-expected profits for the last three months of 2021 as the company’s Covid-19 vaccine continued to power its year-over-year growth, while executives mulled plans to roll out an additional booster shot.

In the latest quarter, Moderna’s revenue reached $7.21 billion, with nearly all of that coming from vaccine sales. The Cambridge, Mass., company said it distributed a total of 807 million doses of the vaccine, Spikevax, last year.